The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) is a huge mover today! About 197,948 shares traded hands. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has declined 38.21% since April 14, 2016 and is downtrending. It has underperformed by 42.90% the S&P500.
The move comes after 9 months positive chart setup for the $303.84 million company. It was reported on Nov, 16 by Barchart.com. We have $12.56 PT which if reached, will make NASDAQ:SGMO worth $543.87 million more.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) Ratings Coverage
Out of 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 44% are positive. Sangamo Biosciences has been the topic of 12 analyst reports since August 8, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, September 2 by Jefferies. Janney Capital downgraded the stock to “Neutral” rating in Thursday, August 4 report. On Tuesday, September 8 the stock rating was downgraded by Zacks to “Sell”. Piper Jaffray downgraded the stock to “Neutral” rating in Wednesday, October 19 report. The firm has “Buy” rating given on Wednesday, September 2 by Wedbush. The firm has “Buy” rating given on Friday, September 4 by Cowen & Co. The rating was maintained by JP Morgan on Saturday, August 8 with “Overweight”. The firm has “Buy” rating given on Friday, October 23 by Jefferies. The firm has “Neutral” rating given on Wednesday, October 19 by PiperJaffray. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4.
According to Zacks Investment Research, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.”
Insitutional Activity: The institutional sentiment decreased to 0.81 in 2016 Q2. Its down 0.57, from 1.38 in 2016Q1. The ratio turned negative, as 20 funds sold all Sangamo Biosciences, Inc. shares owned while 42 reduced positions. 13 funds bought stakes while 37 increased positions. They now own 45.72 million shares or 4.72% less from 47.99 million shares in 2016Q1.
Jpmorgan Chase & Communication holds 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 771 shares. Princeton Mgmt Incorporated, a New Jersey-based fund reported 124,395 shares. Comerica Bancshares has invested 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Envestnet Asset Mgmt has 0% invested in the company for 2,761 shares. Barclays Pcl reported 16,299 shares or 0% of all its holdings. Moreover, Advisory Services Network Limited Liability Company has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 300 shares. Altrinsic Global Ltd Llc has invested 0.08% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Morgan Stanley has 0% invested in the company for 312,911 shares. First Republic Management has invested 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Quantitative Systematic Strategies Limited Liability Corporation accumulated 0.08% or 28,176 shares. Ubs Asset Mngmt Americas holds 29,398 shares or 0% of its portfolio. Tfs Cap Ltd Liability Corporation holds 0.02% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 20,352 shares. Adage Capital Grp Inc Limited Liability Corporation holds 0.04% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 2.50 million shares. Fic Cap last reported 2.36% of its portfolio in the stock. D E Shaw And Inc owns 113,406 shares or 0% of their US portfolio.
More notable recent Sangamo Biosciences, Inc. (NASDAQ:SGMO) news were published by: Fool.com which released: “Why Sangamo Biosciences, Inc. Fell 29% Today” on August 04, 2016, also Prnewswire.com with their article: “Sangamo BioSciences Announces Third Quarter 2016 Conference Call and Webcast” published on October 19, 2016, Prnewswire.com published: “Sangamo BioSciences Announces Participation In Upcoming Scientific Conferences” on October 17, 2016. More interesting news about Sangamo Biosciences, Inc. (NASDAQ:SGMO) were released by: Prnewswire.com and their article: “Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And …” published on June 01, 2016 as well as Prnewswire.com‘s news article titled: “Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX …” with publication date: September 06, 2016.
SGMO Company Profile
Sangamo Biosciences Inc., incorporated on June 22, 1995, is a clinical-stage biopharmaceutical company. The Firm is focused on the research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The Firm is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics, which are therapeutic products for the treatment of genetic disease. The Company’s ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. The Firm has preclinical programs in hemophilia A and other Lysergic acid diethylamide (LSDs), and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.